UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis

Journal of hepatology, 2017, Vol.66 (1), p.S434-S434

2017

Volltextzugriff (PDF)

EDP-494 is a Potent Pan-Genotypic Cyclophilin Inhibitor for HCV Infection, including DAA Resistance Associated Variants (RAVS)

Journal of hepatology, 2016, Vol.64 (2), p.S414-S414

2016

Volltextzugriff (PDF)

A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease

Journal of hepatology, 2017, Vol.66 (1), p.S657-S657

2017

Volltextzugriff (PDF)

A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis

Journal of hepatology, 2017, Vol.66 (1), p.S165-S165

2017

Volltextzugriff (PDF)

1213 CYCLOPHILIN INHIBITOR EDP-546 IS A POTENTIAL CORNERSTONE DRUG FOR USE IN COMBINATION WITH NS5A AND PROTEASE INHIBITORS DUE TO ITS HIGH BARRIER TO HCV RESISTANCE

Journal of hepatology, 2013-04, Vol.58, p.S493-S493

2013

Volltextzugriff (PDF)

1200 ANTIVIRAL ACTIVITY OF EP-NI266, A POTENT NUCLEOTIDE HCV POLYMERASE INHIBITOR

Journal of hepatology, 2012-04, Vol.56, p.S475-S476

2012

Volltextzugriff (PDF)

1213 A HIGHLY POTENT HCV NS5A INHIBITOR EDP-239 WITH FAVORABLE PRECLINICAL PHARMACOKINETICS

Journal of hepatology, 2011-03, Vol.54, p.S479-S479

2011

Volltextzugriff (PDF)

8 POTENT HCV PROTEASE INHIBITORS WITH THE POTENTIAL FOR ONCE-DAILY DOSING AND BROAD GENOTYPE COVERAGE

Journal of hepatology, 2009, Vol.50, p.S6-S6

2009

Volltextzugriff (PDF)

P2091 In vitro-in vivo clearance correlation of EDP-420, clarithromycin and telithromycin

International journal of antimicrobial agents, 2007, Vol.29, p.S604-S604

2007

Volltextzugriff (PDF)

THU-469 - EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms

Journal of hepatology, 2018-04, Vol.68, p.S341-S342

2018

Volltextzugriff (PDF)

EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms

Journal of hepatology, 2018-04, Vol.68, p.S341-S342

2018

Volltextzugriff (PDF)

P2093 Tissue distribution of [14C]-EDP-420 in the rat by quantitative whole-body autoradiography

International journal of antimicrobial agents, 2007, Vol.29, p.S605-S605

2007

Volltextzugriff (PDF)

P2092 Preclinical pharmacokinetics and interspecies scaling of EDP-420, afirst-in-class bicyclolide

International journal of antimicrobial agents, 2007, Vol.29, p.S604-S605

2007

Volltextzugriff (PDF)

FRI-363 - EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis

Journal of hepatology, 2017, Vol.66 (1), p.S434-S434

2017

Volltextzugriff (PDF)

PS-032 - Discovery of a novel core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model

Journal of hepatology, 2018-04, Vol.68, p.S19-S19

2018

Volltextzugriff (PDF)

FRI-084 - EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo

Journal of hepatology, 2018-04, Vol.68, p.S398-S398

2018

Volltextzugriff (PDF)

Discovery of a novel core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model

Journal of hepatology, 2018-04, Vol.68, p.S19

2018

Volltextzugriff (PDF)

EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo

Journal of hepatology, 2018-04, Vol.68, p.S398

2018

Volltextzugriff (PDF)

THU-250 - EDP-494 is a Potent Pan-Genotypic Cyclophilin Inhibitor for HCV Infection, including DAA Resistance Associated Variants (RAVS)

Journal of hepatology, 2016, Vol.64 (2), p.S414-S414

2016

Volltextzugriff (PDF)

SAT-459 - A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease

Journal of hepatology, 2017, Vol.66 (1), p.S657-S657

2017

Volltextzugriff (PDF)

Motor Learning

Comprehensive Physiology, 2019-03, Vol.9 (2), p.613-663

2019

Volltextzugriff (PDF)

Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake

Comprehensive Physiology, 2020-07, Vol.10 (3), p.785-809

2020

Volltextzugriff (PDF)

THU-377 - A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis

Journal of hepatology, 2017, Vol.66 (1), p.S165-S165

2017

Volltextzugriff (PDF)

Oxidative Stress in Pulmonary Fibrosis

Comprehensive Physiology, 2020-04, Vol.10 (2), p.509-547

2020

Volltextzugriff (PDF)

Intestinal Absorption of Bile Acids in Health and Disease

Comprehensive Physiology, 2019-12, Vol.10 (1), p.21-56

2019

Volltextzugriff (PDF)

1 – 25 von 29.913

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23.633)
Mit Volltextzugriff
(25.374)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(17.448)
Life Sciences & Biomedicine
(8.600)
Technology
(7.015)
Physical Sciences
(5.375)
Humans
(3.808)
Physics
(3.649)
Engineering
(3.619)
Exact Sciences And Technology
(3.356)
Biological And Medical Sciences
(2.875)
Materials Science
(2.791)
Female
(2.381)
Animals
(2.103)
Materials Science, Multidisciplinary
(2.024)
Male
(1.999)
Chemistry
(1.918)
Applied Sciences
(1.892)
Fundamental And Applied Biological Sciences. Psychology
(1.716)
Engineering, Electrical & Electronic
(1.473)
Adult
(1.376)
Medical Sciences
(1.355)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta
(14.999)
Elsevier ScienceDirect Journals Complete
(10.846)
Free E-Journal (出版社公開部分のみ）
(8.469)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(7.057)
MEDLINE
(6.233)
Journals@OVID
(4.145)
IEEE Xplore
(2.853)
IngentaConnect Journals
(2.816)
NUS Single-Journal Subscriptions
(2.542)
springer (창간호~2014)
(2.184)
Wiley-Blackwell Journals
(2.041)
Wiley Online Library Full Collection 2018
(1.271)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.197)
Taylor & Francis Journals
(660)
Oxford journals
(648)
Taylor & Francis Online
(629)
Taylor & Francis Online
(587)
Ebook Central Perpetual and DDA
(522)
eBooks on EBSCOhost
(512)
American Physical Society
(425)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis

EDP-494 is a Potent Pan-Genotypic Cyclophilin Inhibitor for HCV Infection, including DAA Resistance Associated Variants (RAVS)

A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease

A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis

1213 CYCLOPHILIN INHIBITOR EDP-546 IS A POTENTIAL CORNERSTONE DRUG FOR USE IN COMBINATION WITH NS5A AND PROTEASE INHIBITORS DUE TO ITS HIGH BARRIER TO HCV RESISTANCE

1200 ANTIVIRAL ACTIVITY OF EP-NI266, A POTENT NUCLEOTIDE HCV POLYMERASE INHIBITOR

1213 A HIGHLY POTENT HCV NS5A INHIBITOR EDP-239 WITH FAVORABLE PRECLINICAL PHARMACOKINETICS

8 POTENT HCV PROTEASE INHIBITORS WITH THE POTENTIAL FOR ONCE-DAILY DOSING AND BROAD GENOTYPE COVERAGE

P2091 In vitro-in vivo clearance correlation of EDP-420, clarithromycin and telithromycin

THU-469 - EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms

EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms

P2093 Tissue distribution of [14C]-EDP-420 in the rat by quantitative whole-body autoradiography

P2092 Preclinical pharmacokinetics and interspecies scaling of EDP-420, afirst-in-class bicyclolide

FRI-363 - EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis

PS-032 - Discovery of a novel core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model

FRI-084 - EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo

Discovery of a novel core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model

EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo

THU-250 - EDP-494 is a Potent Pan-Genotypic Cyclophilin Inhibitor for HCV Infection, including DAA Resistance Associated Variants (RAVS)

SAT-459 - A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease

Motor Learning

Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake

THU-377 - A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis

Oxidative Stress in Pulmonary Fibrosis

Intestinal Absorption of Bile Acids in Health and Disease

Suchergebnisse filtern